Glycemia Care
Natural health product licensed in Canada
- Licence holder
- Mapleland Enterprises Inc.
- NPN or DIN-HM
- 80116985
- Status
- Active licence
- Licence date
- 8 March 2022
- Revision date
- Not provided
- Form
- Capsule, dur
- Route of administration
- Orale
- Application type
- Générale (non traditionelle)
If this product were sold in France
- Dose déclarée au-delà d'une limite
Chrome: up to 48.8 µg a day according to the dosing instructions published by Health Canada (4 unités posologiques par jour au plus, pour les adultes), above the maximum dose of 25 µg set in France for a food supplement (2006 Order, not revised since November 2006).
arrêté du 9 mai 2006, annexe III. French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
- À vérifier
Magnésium: up to 300 mg a day according to the dosing instructions published by Health Canada, above the limite de sécurité from EFSAEuropean Food Safety Authority. for adults (250 mg a day). Pour ce nutriment, le repère de l'EFSA ne porte que sur les apports ajoutés (compléments, aliments enrichis), pas sur ce qu'apporte l'alimentation courante.
limite supérieure de sécurité (UL). EFSA, Overview on Tolerable Upper Intake Levels (version 11, August 2025), retrieved 21 October 2026.
- Conditions légales
Glycine max. (L.) Merr.: La portion journalière recommandée ne doit pas conduire à une ingestion d'isoflavones supérieure à 1 mg/kg de poids corporel (exprimés comme aglycone du composant principal). L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Acide (+-)-1,2-dithiolane-3-pentanoïque Source : Acide DL-alpha-lipoÏque | 75 mg | Not calculated |
| Phaseolus vulgaris Source : Graine Extract : Matériel brut sec Extraction ratio : 10:1 Dry plant equivalent : 900 mg Potency : 270 AAIU Alpha-Amylase Inhibitors | 90 mg | Not calculated |
| Cinnamomum verum Source : Écorce (branche) Extract : Matériel brut sec Extraction ratio : 10:1 Dry plant equivalent : 750 mg | 75 mg | Not calculated |
| Glycine max Source : Graine | 55 mg | Not calculated |
| Magnésium Source : Oxyde de magnésium | 75 mg | 300,000 µg |
| Chrome Source : Picolinate de chrome (III) | 12.2 mcg | 48.8 µg |
Non-medicinal ingredients
Hypromellose, Cellulose microcristalline, Stéarate de magnésium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 19 years | 2 Capsule | 2 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Source of/Provides antioxidants. Source of antioxidants/Provides antioxidants. Helps in energy metabolism, tissue formation and bone development. Helps to maintain normal blood glucose levels. Helps to maintain proper muscle function, including the heart muscle. Helps to maintain the body's ability to metabolize nutrients. Provides support for healthy glucose metabolism.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80116985
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.